期刊文献+

17例儿童川崎病休克综合征的临床分析

Clinical Analysis of Kawasaki Disease Shock Syndrome in 17 Children
下载PDF
导出
摘要 目的:探讨川崎病休克综合征(KDSS)患儿的临床表现、早期识别、治疗方案以及预后。方法:回顾性收集17例KDSS患儿的住院临床资料,同时为每例KDSS患儿选取同期住院的非休克川崎病患儿4例作为对照组,比较其临床特征及实验室特点。结果:KDSS组患儿心脏损害更加严重,KDSS组左室射血分数较对照组下降,氨基末端脑钠肽较对照组显著升高,并能作为有效的早期识别KDSS发生的指标;KDSS组冠脉损害发生率高于对照组;KDSS组患儿血小板计数降低;KDSS组患儿中性粒细胞数、C反应蛋白较对照组患者升高。结论:KDSS是川崎病一种严重的表现形式,其全身炎症及心脏损伤较非休克川崎病患儿更为剧烈。丙种球蛋白和血管活性药物的治疗安全且有效,大多数患儿预后良好。 Objective:To explore the clinical manifestations,early diagnosis,treatment options and prognosis of patients with Kawasaki disease shock syndrome(KDSS).Methods:The clinical data of 17 patients with KDSS were retrospectively collected.Four patients hospitalized at the same time were selected as the control group for each KDSS patient.The clinical characteristics and laboratory characteristics were compared.Results:Heart damage in the KDSS group was more severe.Compared with the control group,the left ventricular ejection fraction in the KDSS group decreased,and the amino terminal brain natriuretic peptide increased,which could be used as an effective indicator for early identification of KDSS.The incidence of coronary artery damage in the KDSS group was significantly higher than that in the control group.The platelet count in the KDSS group decreased;the number of neutrophils and C-reactive protein in the KDSS group were significantly higher than those in the control group.Conclusion:KDSS is a kind of severe form of Kawasaki disease,and its systemic inflammation and cardiac injury are more severe than those of non shock Kawasaki disease.The treatment of gamma globulin and vasoactive drugs is safe and effective,and the follow-up of most patients shows good prognosis.
作者 李晨 仇慧仙 吴蓉洲 褚茂平 Li Chen;Qiu Huixian;Wu Rongzhou;Chu Maoping(The Children’s Hospital,Zhejiang University School of Medicine,Zhejiang Hangzhou 310051,China;The Second Affiliated Hospital,Yuying Children’s Hospital,Institute of Cardiovascular Development and Translational Medicine,Wenzhou Medical University,Zhejiang Wenzhou 325000,China)
出处 《儿科药学杂志》 CAS 2021年第4期19-23,共5页 Journal of Pediatric Pharmacy
关键词 川崎病 休克 心脏损害 Kawasaki disease shock cardiac injury
  • 相关文献

参考文献2

二级参考文献8

  • 1潘柏申,杨振华,吴健民.冠状动脉疾病和心力衰竭时心脏标志物临床检测应用建议[J].中华检验医学杂志,2006,29(9):774-778. 被引量:73
  • 2吴铁吉.病毒性心肌炎诊断标准[J].中华儿科杂志,2000,38(2):75-75.
  • 3Jung B, Adeli K. Clinical laboratory reference intervals in pediatrics:The CALIPER initiative. Clin Biochem, 2009, 42: 1589-1595.
  • 4Clinical and Laboratory Standards Institute. C28-A3 Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline-Third Edition CLSI document.
  • 5Clinical and Laboratory Standards Institute. EP17-A Protocols for Determination of Limits of Detection and Limits of Quantitation. Wayne, PA USA:CLSI, 2004.
  • 6Clinical and Laboratory Standards Institute. EP15-A2 User verification of performance for precision and Trueness. Wayne, PA, USA :CLSI, 2005.
  • 7中国合格评定国家认可委员会.CNAS-CL02:2008医学实验室质量和能力认可准则(ISO15189:2007).北京:中国合格评定国家认可委员会.
  • 8Soldin SJ, Murthy JN, Agarwalla PK, et al. Pediatric Reference Ranges for Creatine Kinase, CKMB, Troponin I, Iron, and Cortisol. Clin Biochem, 1999, 32:77-80.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部